Background: Up-to-date information regarding the recurrence rate of Helicobacter
| INTRODUCTION
In 1983, Warren and Marshall described the Gram-negative, spiralshaped microaerophilic bacterium, Helicobacter pylori (H. pylori) that colonises the human stomach. Numerous studies have confirmed an aetiologic role of H. pylori in the development of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer. [1] [2] [3] [4] In 1994, the international agency for the research of cancer (IARC) classified H. pylori as a class I (definite) carcinogen for gastric cancer. 5 H. pylori gastritis has been defined as an infectious disease, 6 whose modes of transmission include oral-oral, faecal-oral and gastro-oral. 7 The global prevalence of H. pylori infection has remained high, especially in countries with low socioeconomic status and poor sanitary conditions. 8, 9 While the successful eradication of H. pylori can prevent development and progression of H. pylori-associated diseases, 10 the efficacy of H. pylori treatment regimens has decreased because of increasing antibiotic resistance.
11
H. pylori recurrence also remains an unsolved problem. 12 Multiple studies have been conducted in different regions and across several years regarding H. pylori recurrence. For example, in 2005, Gisbert et al 12 reviewed the recurrence rate of H. pylori infection and analysed factors thought to influence it. They reported that a worldwide mean annual recurrence rate of H. pylori infection of 4.5% (95% CI, [4] [5] . Recurrence was more frequent in developing countries (calculated annual recurrence rate of 13%) compared to developed countries (calculated annual recurrence rate of 2.7%). 13 Yan et al 14 reported that there was an inverse relation between H.
pylori recurrence and socioeconomic development according to the human development index (HDI).
Recurrence can occur either by recrudescence or reinfection.
Recrudescence is defined as reappearance of the original infection that was temporarily suppressed leading to false results tests regarding eradication. Reinfection is defined as infection with a new strain of H. pylori or recurrence of infection after an as yet undefined period (eg, 6 months to 2 years). 15 Recrudescence is most common when low efficiency therapies are used. 16 Reinfection requires reexposure and is therefore more likely in countries with high H. pylori prevalence and poor sanitation. 13 The lack of widely available methods to compare whether then new infection differs from the original infection requires that most studies rely on the duration between the end of therapy and discovery of the recurrence. pylori" or "Hp" and "recurrence" or "recrudescence" or "reinfection" or "recurrent" or "recurred" or "re-infect*" or "relapse*." The search was restricted to human studies and literature written in English.
Relevant papers were also identified from the reference lists of previous papers.
| Study selection
Our analysis was based on studies of adults that assessed H. pylori status after eradication therapy with a follow-up of at least 12 months.
| Exclusion criteria
The exclusion criteria for our analysis were: (1) research in children,
(2) a follow-up time after successful eradication of less than 12 months, (3) missing important data (accurate follow-up time and recurrence rate) and (4) basic research, systematic reviews, metaanalyses and conference presentations. CI. Heterogeneity was assessed using a Chi-square test and I 2 statistics (P value <.10 or I 2 over 50% were defined as substantial heterogeneity). Egger's test was used to assess publication bias and implemented using R software. The methodological quality of included studies was assessed using an 11-item checklist recommended by agency for healthcare research and quality (AHRQ) 19 .
Meta regression analysis was used to compare the differences among groups using R software. The covariates of Meta regression analysis included HDI, H. pylori prevalence, periods and regions.
3 | RESULTS
| Study selection
Totally, 7133 records were identified of which 3802 were duplicates, 2981 records were excluded by title or abstract, and 218 records were excluded based on selection criteria ( Figure 1 ). One hundred and thirty-two studies (one study conducted in 7 sites in 6 Latin American countries was divided into "7 studies" for the following analysis because different HDI, H. pylori prevalence and geographic region were observed among the countries) met our inclusion criteria and were included in the analysis. The primary results included Author (publication date), country, methods, eradication treatment, time for defining eradication (weeks), reinfection/recrudescence/recurrence cases, sample size, follow-up (patient-years), annual reinfection/recrudescence/recurrence rate, DNA fingerprint, HDI and Local H. pylori prevalence (Table S1 ). All of the included studies were assessed for methodological quality (Table S2) . Sixty-six studies were of high quality and 66 studies were of moderate quality. H. pylori recurrence was analysed over a total follow-up of 53 934 patientyears after successful eradication in H. pylori-positive patients. Each article was weighted according to the patient-years of follow-up. In total, the mean annual recurrence rate for the entire group studies was 4.3% (95% CI, 4-5) ( Figure S1 ). Significant heterogeneity was observed for pooled analysis of total recurrence rate (I 2 = 93%,
Helicobacter pylori reinfection and recrudescence were analysed separately in the subgroup of 39 studies (16 111 patient-years) conducting DNA fingerprinting techniques or having the results of recurrence during 6-months period, the mean annual reinfection and recrudescence rate were 3.1% (95% CI, 2-5) and 2.2% (95% CI, 1-3), respectively ( Figures S2-S3 ). Significant heterogeneity was observed for pooled analysis of reinfection rate (I 2 = 93%, P <.01) and recrudescence rate (I 2 = 91%, P <.01). The funnel plot showed that the included studies were reasonably well scattered ( Figure S4 ). No statistical evidence of publication bias was observed among studies using Egger's test (P = .09) ( Figure S5 ).
In the USA, the pooled H. pylori recurrence rate was 1.0% (95% CI, 0. 
| Helicobacter pylori recurrence rate and HDI
The HDI was classified as very high, high, medium and low. There were significant differences among groups (P <.01) ( Table S3 ). The mean annual recurrence rate was highest (10.9%, 95% CI 6-18) in the subgroup of 13 studies conducted in countries with a medium or low HDI ( Figure S28 ). In the subgroup of 31 studies conducted in countries with a high HDI, the mean annual recurrence rate was 6.2% (95% CI, 4-8) ( Figure S29 ). The mean annual recurrence rate was lowest (3.1%, 95% CI 2-4) in the subgroup of 94 studies conducted in countries with a very high HDI ( Figure S30 ). Significant heterogeneity was observed for pooled analysis of recurrence rate in the subgroup of countries with a medium or low HDI (I 2 = 93%, P <.01), a high HDI (I 2 = 94%, P <.01) and a very high HDI (I 2 = 92%, P <.01).
| Helicobacter pylori recurrence rate and local H. pylori prevalence
The local H. pylori prevalence was classified from >70% to <30%.
Significant differences were observed among groups (P <.01) (Table S4) . Among the 21 studies conducted in countries with a very high H. pylori prevalence ( >70%), the mean annual recurrence rate was 10.9% (95% CI, 7-16) ( Figure S31 ). Among the 69 studies conducted in countries with a relatively high H. pylori prevalence (50-70%), the mean annual recurrence rate was 3.7% (95% CI, 3-5) (Figure S32) . Among the 37 studies conducted in countries with a HU ET AL.
| 775 medium H. pylori prevalence (30%-50%), the mean annual recurrence rate was 3.4% (95% CI, 2-5) ( Figure S33 ). Among the 11 studies conducted in countries with a low H. pylori prevalence ( <30%), the mean annual recurrence rate was 1.6% (95% CI, 0.5-3) ( Figure S34 ).
Significant heterogeneity was observed for pooled analysis of recurrence rate in the subgroup of countries with a very high H. pylori prevalence (I 2 = 95%, P <.01), a high H. pylori prevalence (I 2 = 94%, P <.01), a medium H. pylori prevalence (I 2 = 92%, P <.01) and a low H. pylori prevalence (I 2 = 68%, P <.01).
| Helicobacter pylori recurrence rate during different periods
Three time periods (1990s, 2000s and 2010s) were used to evaluate H. pylori recurrence trends over time. The mean annual recurrence rate reported during the 1990s (3.9%, 95% CI 3-5), 2000s (4.4%, 95% CI 3-6) and 2010s (4.8%, 95% CI 3-7) did not change significantly (P = .75) (Table S5 ) (Figures S35-S37 ). Significant heterogeneity was observed for pooled analysis of recurrence rate in the 1990s (I 2 = 88%, P <.01), 2000s (I 2 = 94%, P <.01) and 2010s (I 2 = 97%, P <.01). The mean annual recurrence rates in Africa, Asia, Europe, North America, South America, and Oceania were 1.5% (95% CI, 0-5), 5.6% (95% CI, 4-7), 2.7% (95% CI, 2-4), 6.2% (95% CI, 4-9), 7.7%
(95% CI, 4-13) and 2.0% (95% CI, 0.5-4), respectively ( Figures S38-S43 ). Significant differences were observed among Europe and Asia (P<0.01), Europe and North America (P <.01), Europe and South America (P <.01), Oceania and North America (P <.05), Oceania and South America (P <.05) (Table S6 ). Significant heterogeneity was observed for pooled analysis of recurrence rate in Asia (I 2 = 96%, P <.01), Europe (I 2 = 90%, P <.01), North America (I 2 = 86%, P <.01), South America (I 2 = 95%, P <.01) and Oceania (I 2 = 80%, P <.01).
| DISCUSSION
Helicobacter pylori is a serious human pathogen that causes chronic progressive gastric mucosal damage and clinical diseases such as peptic ulcer disease, atrophic gastritis, dyspepsia, mucosa-associated lymphoid tissue lymphoma and gastric cancer. 6, 20, 21 The successful eradication of H. pylori results in healing of chronic active gastritis and prevents progression to gastric atrophy, improves dyspeptic symptoms, heals gastric and duodenal ulcers, cures the majority of cases of early-stage (Lugano I/II) low-grade MALT lymphoma and reduces the incidence of gastric cancer. 6, 10 Recurrence either as recrudescence (inadequate treatment) and reinfection eliminates the benefits of H. pylori eradication.
In this review, we examined 132 studies from 45 countries or regions to evaluate the recurrence rates after H. pylori therapy. Ideally, H. pylori recurrence is defined as a reinfection when all recurrences in the first six months after eradication are excluded as recrudescence or the infections are assessed using DNA fingerprinting. However, Only 39 of the 132 studies (16 111 patient-years)
conducted DNA fingerprinting or showed the data for recurrence cases in the first six months. For that subgroup of well-defined subjects, the annual reinfection rate was 3.1% (95% CI, 2-5). For the entire group, the mean annual recurrence rate was slighter higher 14 H. pylori recurrence tended to follow socioeconomic development as assessed using HDI. We found that H. pylori recurrence was the highest in medium-and low-HDI countries (10.9%, 95% CI 6-18), followed by those with a high HDI (6.2%, 95% CI 4-8) or a very high HDI (3.1%, 95% CI 2-4). These results are consistent with reports by Gisbert et al 12 and Niv et al. 13 However, Ireland, [22] [23] [24] [25] [26] Chile, 27 Singapore, 28 Greece, 29, 30 or not available six months post-treatment for many studies. While this may influence the accurate calculation of reinfection and recrudescence rates in the subpopulation with molecular testing.
Seventh, we used the keywords ("Helicobacter pylori" or "H. pylori" or "Hp" and "recurrence" or "recrudescence" or "reinfection" or "recurrent" "recurred" or "re-infect*" or "relapse*.") to search the relevant papers. Moreover, relevant papers were also identified from the reference lists of previous papers. However, studies that did not mention the keywords in titles/abstracts might have been missed in this review.
In conclusion, H. pylori recurrence remains a problem that is closely associated with socioeconomic and sanitary conditions. Worldwide elimination of H. pylori will require attention to reducing both recrudescence through the use of more effective eradication regimens and reinfection. For example, it may be possible to reduce exposure to infected individuals and sources via community wide eradication. Further studies in different geographical regions with longer follow-up times and a greater number of patients are needed to thoroughly evaluate the recurrence rate of H. pylori.
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